Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- -hydroxylase inhibitors.
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology; D003987:Dibenzothiazepines / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D013116:Spinal Cord / Q000378:metabolism*; D013141:Spiro Compounds / Q000494:pharmacology; D013859:Thiocarbamates / Q000494:pharmacology*; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors
D001562:Benzimidazoles; D003987:Dibenzothiazepines; D008781:Methyltyrosines; D013141:Spiro Compounds; D013859:Thiocarbamates; D014149:Tranquilizing Agents; D006899:Mixed Function Oxygenases; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D006220:Haloperidol; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine